SG/CALL/ELI LILLY & CO/980/0.1/17.01.25 | Real-time Bid/Ask 02:34:42 09/05/2024 pm IST | ||
| 2.63 EUR / 2.67 EUR | -1.85% |
|
| Current month | +27.96% | ||
| 1 month | -27.61% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change | Volume |
|---|---|---|---|
| 09/24/09 | 2.65 | -1.85% | 0 |
| 08/24/08 | 2.7 | +17.39% | 0 |
| 07/24/07 | 2.3 | +25.68% | 0 |
| 06/24/06 | 1.83 | -10.29% | 0 |
| 03/24/03 | 2.04 | -24.72% | 0 |
Delayed Quote Börse Stuttgart
Last update May 09, 2024 at 12:52 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SU92YJ |
| ISIN | DE000SU92YJ3 |
| Date issued | 29/02/2024 |
| Strike | 980 $ |
| Maturity | 17/01/2025 (254 Days) |
| Parity | 10 : 1 |
| Emission price | 3.3 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.39 € |
|---|---|
| Lowest since issue | 1.83 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
27
Last Close Price
775
USD
Average target price
848.3
USD
Spread / Average Target
+9.46%
- Stock Market
- Warrants
- Warrant